10-K: Nika Pharmaceuticals Reports Full Year 2023 Results, Focuses on Growth and Strategic Partnerships

Nika Pharmaceuticals reported a net loss of $64,833 for 2023, a significant decrease from the $3,183,715 loss in 2022, as the company transitions its business focus towards pharmaceutical and dietary supplement development.

Summary

• Nika Pharmaceuticals, Inc. filed its annual report for the fiscal year ended December 31, 2023.
• The company reported a net loss of $64,833 for 2023, a substantial improvement compared to the $3,183,715 loss in 2022.
• General and administrative expenses increased by 92.3% to $64,833 in 2023, primarily due to higher professional and investor relations fees.
• Consulting expenses decreased from $150,000 in 2022 to $0 in 2023.
• The company did not generate any revenue in 2023 or 2022.
• Nika Pharmaceuticals is focusing on the development and distribution of pharmaceutical products and dietary supplements through exclusive rights agreements and strategic partnerships.
• The company has a going concern qualification from its auditors, indicating substantial doubt about its ability to continue as a going concern.
• As of December 31, 2023, the company had an accumulated deficit of $3,400,247.
• The company is seeking additional debt and/or equity financing to sustain its operations.
• As of March 22, 2024, there were 876,090,000 shares of the company's common stock outstanding.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a going concern qualification and lack of revenue, despite some positive strategic moves. The overall sentiment is negative due to the company's financial instability and reliance on related party funding.

Positives

• The company significantly reduced its net loss year-over-year.
• Nika has secured exclusive rights to key pharmaceutical and dietary supplement products.
• The company has established strategic partnerships to support its growth and development.
• The acquisition of a stake in Nika Europe, Ltd. provides a foothold in key international markets.

Negatives

• The company has not generated any revenue to date.
• Nika has a significant accumulated deficit of $3,400,247.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is reliant on related party loans to fund operations.

Risks

• The company's ability to continue as a going concern is uncertain due to its lack of revenue and accumulated deficit.
• Nika is dependent on securing additional financing to sustain its operations.
• The company faces risks related to changes in economic conditions, legislative/regulatory changes, and competition.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is reliant on related party loans to fund operations.

Future Outlook

Management believes the Company will continue to incur losses and negative cash flows from operating activities for the foreseeable future and will need additional equity or debt financing to sustain its operations until it can achieve profitability and positive cash flows, if ever.

Management Comments

• Management plans to seek additional debt and/or equity financing for the Company.
• Our current management has agreed to advance funds to the Company on an as needed basis.

Industry Context

The company's shift towards pharmaceutical and dietary supplement development aligns with the growing global demand for health and wellness products. The company's focus on exclusive rights and strategic partnerships is a common strategy in the pharmaceutical industry to secure market access and intellectual property.

Comparison to Industry Standards

• Nika Pharmaceuticals is a very early stage company with no revenue, which is not uncommon for companies in the development phase of the pharmaceutical and dietary supplement industry.
• The company's reliance on related party loans is not unusual for early-stage companies, but it does highlight the need for external funding.
• The going concern qualification from the auditors is a significant concern and is not typical for established companies in the industry.
• The company's lack of internal controls is a significant weakness and needs to be addressed to meet industry standards for financial reporting.

Management Changes

Corporate Governance

Related Party Transactions

• The company received $83,565 in loan proceeds from a related party in 2023 and $24,180 in 2022.
• The company owes $101,745 to a related party as of December 31, 2023.
• The company issued 8,000,000 shares of Preferred stock to a related party for an Exclusive Rights Agreement.
• The company issued 2,000,000 shares of Preferred stock to a related party for an Exclusive Rights Agreement.
• Mr. Ray forgave $30,018 that was due to him from the Company.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern qualification.
• Employees may be impacted by the company's financial challenges and potential need for restructuring.
• Customers and suppliers may be affected by the company's ability to fulfill its obligations.
• Creditors face risk due to the company's financial instability and reliance on related party loans.

Next Steps

• The company will seek additional debt and/or equity financing.
• The company will continue to develop and commercialize its pharmaceutical and dietary supplement products.
• The company will work to address the material weaknesses in its internal control over financial reporting.
• The company will complete the merger with Nika BioTechnology, Inc.

Key Dates

Keywords

Pharmaceuticals, Dietary Supplements, Exclusive Rights, Strategic Partnerships, Emerging Growth Company, Going Concern, Net Loss, OTC Markets, Nika Europe, Internal Control Weaknesses